All Oncology News

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.

Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.

Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

A biologics license application (BLA) has been submitted to the FDA for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma, according to an announcement from Janssen.

The phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia will continue as planned without modifications following a recommendation from the Independent Data Monitoring Committee.

Neoadjuvant treatment with nivolumab (Opdivo) plus platinum doublet chemotherapy showed superior major pathological response rates and pathological complete response rates compared with nivolumab monotherapy among patients with resectable non–small cell lung cancer even for patients with a PD-L1 expression of 50% or greater.

Using circulating tumor cell count as a guide to first-line treatment, either with chemotherapy or endocrine therapy, resulted in an improvement in overall survival compared with physician’s choice of treatment without CTC count for patients with metastatic, hormone receptor–positive/HER2-negative breast cancer.

Treatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Lifileucel achieved safety and efficacy irrespective of the number of aldesleukin doses administered to patients with advanced melanoma.

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

Palbociclib plus fulvestrant did not elicit a progression-free survival benefit vs fulvestrant alone in patients with estrogen receptor–positive/HER2-negative breast cancer who had progressed on prior treatment with a CDK4/6 inhibitor and aromatase inhibitor.

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

Two separate doses of single-agent camizestrant monotherapy improved progression-free survival vs standard-of-care fulvestrant in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.

ASTRO has updated guidance for the use of radiation therapy and systemic therapy for patients who’ve undergone surgery for endometrial cancer. The guideline also considers the role of surgical staging and molecular profiling techniques in determining whether a patient should receive post-operative therapy.

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.

The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.

Concurrent adagrasib and pembrolizumab produced preliminary activity when administered as first-line treatment in patients with non–small cell lung cancer harboring a KRAS G12C mutation, irrespective of PD-L1 status, according to data from the KRYSTAL-1 phase 1b and the KRYSTAL-7 phase 2 cohorts.

Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.

Eribulin mesylate demonstrated a trend toward improved outcomes vs other chemotherapy options of physician’s choice in patients with HER2-low or HER2-0 metastatic breast cancer who were previously treated with at least 1 chemotherapy.

Patients with non-metastatic breast cancer undergoing treatment who added yoga to conventional exercises experienced improvements in disease-free survival, overall survival, and long-term quality of life vs those who did conventional exercises alone.

Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.

Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.

Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.

Oncopeptides AB announced December 7, 2022, that the FDA has asked the company to withdraw melphalan flufenamide from the US market.

Pancreatic cancer often lurks as a silent disease. With no known symptoms, it can progress undetected and spread to other organs.

A study published by researchers at Fox Chase Cancer Center suggests that race itself may predict disparate outcomes between patients with head and neck cancer.

The combination of vusolimogene oderparepvec and nivolumab generated promising responses in patients with cutaneous melanoma who failed previous anti–PD-1 therapy, according to initial data from the phase 2 IGNYTE trial.